Cellectar Biosciences (CLRB) announced that the first patient has been enrolled in the Phase 1b trial of CLR 121125 for the potential treatment of triple negative breast cancer.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLRB:
- Cellectar Biosciences upgraded to Buy from Hold at Maxim
- Cellectar Biosciences Charts Risky Path to Approvals
- Cellectar Biosciences price target lowered to $14 from $18 at Roth Capital
- Cellectar Biosciences reports FY25 EPS ($8.35) vs ($41.89) last year
- CLRB Upcoming Earnings Report: What to Expect?